Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$118M in Q4 2021 → $42.4M now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| RP Recursion Pharmaceuticals In | 100.0% | Trimmed 33% | 3,985,087 | $42.4M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2022 · filed November 14, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| RP Recursion Pharmaceuticals In | Trimmed | −1,992,544 | −$21.2M | 100.0% |
quarter ended June 30, 2022 · filed July 28, 2022
No position changes this quarter.
quarter ended March 31, 2022 · filed May 10, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lilium N V | Exited | −1,745,627 | −$12.1M | — |
| Planet Labs Pbc | Exited | −499,571 | −$3.07M | — |
Loading...
